In Moscow on March 16, 2026, a meeting was held between representatives of the pharmaceutical industries of India and Russia. Those in attendance included delegates from Indian and Russian pharmaceutical companies, active pharmaceutical ingredient (API) manufacturers, and representatives from the Pharmacovigilance authority.
The event outlined the incentives available to Indian pharmaceutical companies entering the Russian market: the opportunity to obtain preferential investment loans, establish production in special economic zones, and participate in offset contracts. Winning such contracts can guarantee up to ten years of uninterrupted product sales for goods manufactured locally in Russia. Representatives of the Indian pharmaceutical industry also shared their plans for cooperation with Russia, noting that they possess a list of medications from the Ministry of Industry and Trade requiring import substitution.
In her address, Victoria Korotenko, Head of Foreign Registration at the Autonomous Non-Commercial Organization “National Scientific Center for Pharmacovigilance,” stated that the organization is prepared to assist Indian pharmaceutical companies with drug registration, safety monitoring, and the submission of clinical trial data.
“We help our international colleagues prepare their drug registration dossiers in the required format and provide support throughout the entire process. We also assist foreign companies in preparing drug safety reports,” the expert emphasized.
Korotenko also noted that the Pharmacovigilance center frequently receives inquiries from representatives in India and other countries regarding which clinical trial data is accepted and whether new trials are necessary.
“Indian pharmaceutical companies can submit information on clinical trials conducted in India during the registration process, but these must comply with international standards. If a drug is already well-established in the market, new clinical trials may not be required. However, it is also possible that companies may be asked to conduct repeat studies for generics or biosimilars,” she stated.
The expert further reminded that Indian manufacturers selling their products in Russia are required to report any adverse events that occur in patients using their medications.
In 2024, Russia and India agreed to collaborate on drug development.
